Overview of first-salvage chemotherapy regimens since 2010
| Study . | N . | Intervention . | Refractory, n (%) . | CR pre-ASCT . | ORR pre-ASCT . | PFS . | OS . |
|---|---|---|---|---|---|---|---|
| Josting et al (2010)13 (RCT) | 279 | DHAP | 0 (0) | CT: 24% | CT: 71% | 3 years: 69% (no significant difference between arms) | 3 years: 85% (no significant difference between arms) |
| Moskowitz et al (2010)14 | 105 | ICE | 48 (46) | PET/gallium: 61% CT: 33% | CT: 59% | 4 years: 56% | 4 years: 72% |
| Moskowitz et al (2012)11 | 97 | ICE + GVD (PET-adapted sequential) | 41 (42) | PET: 60% after ICE 78% after GVD | — | 51 months: 70% | 51 months: 80% |
| Labrador et al (2014)15 (retrospective) | 82 | ESHAP | 41 (50) | PET/gallium: 50% | PET/gallium: 67% | Median PFS: 56 months | 5 years: 73% |
| Santoro et al (2016)16 | 58 | BeGEV | 27 (46) | PET: 73% | PET: 83% | 5 years: 59% | 5 years: 78% |
| Study . | N . | Intervention . | Refractory, n (%) . | CR pre-ASCT . | ORR pre-ASCT . | PFS . | OS . |
|---|---|---|---|---|---|---|---|
| Josting et al (2010)13 (RCT) | 279 | DHAP | 0 (0) | CT: 24% | CT: 71% | 3 years: 69% (no significant difference between arms) | 3 years: 85% (no significant difference between arms) |
| Moskowitz et al (2010)14 | 105 | ICE | 48 (46) | PET/gallium: 61% CT: 33% | CT: 59% | 4 years: 56% | 4 years: 72% |
| Moskowitz et al (2012)11 | 97 | ICE + GVD (PET-adapted sequential) | 41 (42) | PET: 60% after ICE 78% after GVD | — | 51 months: 70% | 51 months: 80% |
| Labrador et al (2014)15 (retrospective) | 82 | ESHAP | 41 (50) | PET/gallium: 50% | PET/gallium: 67% | Median PFS: 56 months | 5 years: 73% |
| Santoro et al (2016)16 | 58 | BeGEV | 27 (46) | PET: 73% | PET: 83% | 5 years: 59% | 5 years: 78% |
BeGEV, bendamustine, gemcitabine, and vinorelbine.